Apotex Warning Letter Demands List Of Products That Might Enter U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA already has Bangalore, India plant on an import alert, but the agency may be preparing to go after API from the facility as well after finding persistent use of questionable testing data.
You may also be interested in...
Apotex Biosimilar Goes To FDA, But May Enter Crowded Market
Pegfilgrastim product, a collaboration with the Indian firm Intas, may have to compete with multiple filgrastim products, along with its reference biologic, Amgen’s Neulasta.
Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes
Report says aggressive enforcement in recent years has forced capacity offline, which led to shortages.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.